1.91

3.24% 0.06

Tvardi Therapeutics Inc (TVRD)

Overview News Price History Discussions Forecast

Tvardi Therapeutics Inc stock is traded at $1.91, with a volume of 73,276. It is up +3.24% in the last 24 hours and down -5.91% over the past month. Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Previous Close:

$1.85

Open:

$1.85

24h Volume:

73,276

Relative Volume:

0.03

Market Cap:

$25.48M

Revenue:

$2.14M

Net Income/Loss:

$-15.44M

P/E Ratio:

-0.6172

EPS:

-3.0946

Net Cash Flow:

$-24.67M

1W Performance:

+4.95%

1M Performance:

-5.91%

6M Performance:

-52.49%

1Y Performance:

-93.73%

1-Day Range:

$1.81

$1.92

1-Week Range:

$1.745

$1.92

52-Week Range:

$1.50

$43.65

Tvardi Therapeutics Inc Stock (TVRD) Company Profile

Name

Tvardi Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(713) 489-8654

Address

3 SUGAR CREEK CTR. BLVD., SUGAR LAND

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

TVRD's Discussions on Twitter

Compare TVRD vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TVRD Tvardi Therapeutics Inc	1.91	24.41M	2.14M	-15.44M	-24.67M	-3.0946
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-20-26	Downgrade	Barclays	Equal Weight → Underweight
Oct-14-25	Downgrade	Barclays	Overweight → Equal Weight
Oct-14-25	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-13-25	Initiated	Barclays	Overweight
Oct-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-13-25	Downgrade	Piper Sandler	Overweight → Neutral
Jul-14-25	Initiated	Raymond James	Outperform
Jul-11-25	Initiated	Cantor Fitzgerald	Overweight
Jun-12-25	Initiated	Piper Sandler	Overweight
May-21-25	Initiated	Oppenheimer	Outperform
May-15-25	Initiated	BTIG Research	Buy
Jun-13-24	Downgrade	Canaccord Genuity	Buy → Hold
Jun-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-13-24	Downgrade	Needham	Buy → Hold
Jun-13-24	Downgrade	Stifel	Buy → Hold
Mar-08-23	Downgrade	BofA Securities	Neutral → Underperform
Mar-08-22	Upgrade	JP Morgan	Neutral → Overweight
Nov-01-21	Resumed	Canaccord Genuity	Buy
Aug-03-21	Initiated	JP Morgan	Neutral
Apr-21-20	Reiterated	H.C. Wainwright	Buy
Aug-12-19	Reiterated	H.C. Wainwright	Buy
May-29-19	Reiterated	Laidlaw	Buy
Feb-06-19	Resumed	Jefferies	Buy
Jan-15-19	Initiated	BofA/Merrill	Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Jefferies	Buy
Aug-08-18	Reiterated	Stifel	Buy
Jun-28-18	Reiterated	H.C. Wainwright	Buy
Mar-12-18	Resumed	H.C. Wainwright	Buy
Feb-12-18	Upgrade	Janney	Neutral → Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy

View All

Tvardi Therapeutics Inc Stock (TVRD) Latest News

Aug 20, 2026

Tvardi stock falls as investors book gains after Phase 1 data - scanx.trade

Aug 20, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 20, 2026

BTIG Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 20, 2026

Aug 19, 2026